{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.1","value":"-3.4"},{"groupId":"OG001","spread":"22.1","value":"-9.4"}]}],"title":"Cycle 2 (n=282,98)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.1","value":"-4.6"},{"groupId":"OG001","spread":"21.4","value":"-6.1"}]}],"title":"Cycle 3 (n=257,86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"-4.8"},{"groupId":"OG001","spread":"24.1","value":"-3.8"}]}],"title":"Cycle 4 (n=236,74)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.8","value":"-6.6"},{"groupId":"OG001","spread":"18.9","value":"-2.7"}]}],"title":"Cycle 5 (n=224,54)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.5","value":"-4.8"},{"groupId":"OG001","spread":"17.1","value":"2.4"}]}],"title":"Cycle 6 (n=195,42)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.8","value":"-4.2"},{"groupId":"OG001","spread":"15.6","value":"-1.5"}]}],"title":"Cycle 7 (n=163,30)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.0","value":"-7.0"},{"groupId":"OG001","spread":"18.6","value":"2.2"}]}],"title":"Cycle 8 (n=130,20)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.2","value":"-5.8"},{"groupId":"OG001","spread":"20.1","value":"6.7"}]}],"title":"Cycle 9 (n=97,15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.2","value":"-8.9"},{"groupId":"OG001","spread":"11.9","value":"1.6"}]}],"title":"Cycle 10 (n=80,7)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.1","value":"-10.5"},{"groupId":"OG001","spread":"8.4","value":"0.0"}]}],"title":"Cycle 11 (n=56,8)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.8","value":"-11.3"},{"groupId":"OG001","spread":"7.7","value":"1.6"}]}],"title":"Cycle 12 (n=48,7)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.3","value":"-10.0"},{"groupId":"OG001","spread":"12.2","value":"2.2"}]}],"title":"Cycle 13 (n=40,5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.8","value":"-10.1"},{"groupId":"OG001","spread":"7.9","value":"0.0"}]}],"title":"Cycle 14 (n=33,5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.0","value":"-13.2"},{"groupId":"OG001","spread":"0.0","value":"0.0"}]}],"title":"Cycle 15 (n=27,3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"-12.3"},{"groupId":"OG001","spread":"6.4","value":"-3.7"}]}],"title":"Cycle 16 (n=19,3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"-7.4"},{"groupId":"OG001","spread":"7.9","value":"-5.6"}]}],"title":"Cycle 17 (n=15,2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.0","value":"-9.1"},{"comment":"There were no participants with available data.","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Cycle 18 (n=11,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.3","value":"1.4"},{"comment":"There were no participants with available data.","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Cycle 19 (n=8,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.1","value":"-5.6"},{"comment":"There were no participants with available data.","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Cycle 20 (n=4,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.4","value":"-3.7"},{"comment":"There were no participants with available data.","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Cycle 21 (n=3,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.8","value":"-1.6"},{"groupId":"OG001","spread":"23.3","value":"-9.0"}]}],"title":"Termination Visit (n=84,37)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"description":"The EORTC QLQ-BM22 assesses the symptoms of bone metastases using 22 items: 5 items for sites of pain, 3 pain characteristics, 8 functional interference aspects, and 6 psychosocial aspects. The pain score was derived from the 3 pain characteristic items. Each item was rated on a 4-point scale, where 1=Not at all to 4=Very much. The pain score was the sum of the 3 pain characteristic scores and was normalized to a scale of 0 to 100. A higher score indicates greater pain. A negative change score indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.","id":"OG001","title":"Treatment of Physician's Choice"}],"paramType":"MEAN","populationDescription":"Randomized population: All participants who were randomized to the study. Only participants with a Baseline pain score and at least 1 post-baseline pain score were included in the analysis. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)","title":"Change From Baseline in the EORTC QLQ-BM22 Pain Score on Day 1 of Each Cycle","type":"SECONDARY","unitOfMeasure":"Units on a scale"}